ERBB2 and breast carcinoma: In the Fo2-1282 mouse model of HER2-positive breast cancer-derived brain metastases, 3-fold higher systemic doses of muMAb4D5/trastuzumab were required to achieve efficacy in brain tumor grafts compared with those in the mammary fat pad.